Long-term Efficacy, Safety and Tolerability of LNP023 in C3G

Inclusion Criteria:

- Patients must have completed the treatment period of the CLNP023X2202 or CLNP023B12301 trial on study drug

Exclusion Criteria:

1. Severe concurrent co-morbidities, e.g. advanced cardiac disease (NYHA class IV), severe pulmonary arterial hypertension (WHO class IV), or any illness or medical condition that in the opinion of the investigator and sponsor is likely to prevent the patient from safely tolerating LNP023 or complying with the requirements of the study
2. Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to screening, or the presence of fever ≥ 38oC (100.4oF) within 7 days prior to screening.
3. History or current diagnosis of ECG abnormalities indicating significant risk of safety for subjects
4. History of HIV or any other immunodeficiency disease